Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ironwood Pharmaceuticals (IRWD) Change in Receivables (2016 - 2025)

Ironwood Pharmaceuticals (IRWD) has disclosed Change in Receivables for 16 consecutive years, with -$73.6 million as the latest value for Q4 2025.

  • Quarterly Change in Receivables fell 1395.27% to -$73.6 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$35.1 million through Dec 2025, up 25.59% year-over-year, with the annual reading at -$35.1 million for FY2025, 25.59% up from the prior year.
  • Change in Receivables hit -$73.6 million in Q4 2025 for Ironwood Pharmaceuticals, down from $34.2 million in the prior quarter.
  • In the past five years, Change in Receivables ranged from a high of $46.4 million in Q2 2025 to a low of -$73.6 million in Q4 2025.
  • Historically, Change in Receivables has averaged -$5.0 million across 5 years, with a median of $1.5 million in 2021.
  • Biggest five-year swings in Change in Receivables: soared 4405.71% in 2022 and later plummeted 1395.27% in 2025.
  • Year by year, Change in Receivables stood at $12.4 million in 2021, then crashed by 107.55% to -$937000.0 in 2022, then surged by 588.47% to $4.6 million in 2023, then increased by 24.19% to $5.7 million in 2024, then tumbled by 1395.27% to -$73.6 million in 2025.
  • Business Quant data shows Change in Receivables for IRWD at -$73.6 million in Q4 2025, $34.2 million in Q3 2025, and $46.4 million in Q2 2025.